Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » Lucence Dx Liquid Biopsy Tech Detects Structural Rearrangements, Breast Cancer Mutations

Lucence Dx Liquid Biopsy Tech Detects Structural Rearrangements, Breast Cancer Mutations

May 29, 2020
|
John Gilmore
Premium

NEW YORK – As part of its push to develop a range of liquid biopsy assays for cancer detection, Lucence Diagnostics has completed two studies that demonstrate the ability of its amplicon-based next-generation sequencing platform, AmpliMark, to detect structural rearrangements (SR) in lung cancer as well as common cancer mutations in breast patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

And Maybe Not

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Now Onto a Hungry Caterpillar

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

This Variant Here

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

Nature Papers Present Tool for Topological Analysis of Chromosomes, Map of Genome-Lipid Associations

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

What's Popular?

In Molecular Diagnostics

  1. Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

  2. Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

  3. Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

    Premium

  4. Vela Diagnostics Receives Second FDA Emergency Use Authorization for SARS-CoV-2 Molecular Test

  5. UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.